Education

Feb 01, 2018

Normal Scores of Deep Breathing Tests: Beware of Dysrhythmia in Transthyretin Amyloidosis

Jan 23, 2018

Obesity is a Significant Susceptibility Factor for Idiopathic AA Amyloidosis

Jan 21, 2018

Psychopathological Dimensions in Subjects With Hereditary ATTR V30M Amyloidosis and Their Relation With Life Events Due to the Disease

Jan 09, 2018

New Concepts in the Treatment and Diagnosis of Amyloidosis

Jan 04, 2018

Persistent Fever and Destructive Arthritis Caused by Dialysis-Related Amyloidosis

Jan 04, 2018

Treatment Patterns and Health Care Resource Utilization Among Patients With Relapsed/Refractory Systemic Light Chain Amyloidosis

Jan 03, 2018

Informed Consent for Clinical Trials

The term informed consent is mistakenly viewed as the same as getting a research participant's signature on the consent form. FDA believes that obtaining a…

Dec 31, 2017

Case Report: Treatment of Light-Chain Amyloidosis With Daratumumab Monotherapy in Two Patients

Dec 21, 2017

Understanding Amyloidosis: Etiology, Epidemiology, Pathophysiology, Management

Dec 19, 2017

Right Ventricular Longitudinal Strain: A Tool for Diagnosis and Prognosis in Light-Chain Amyloidosis

Objectives: Light-chain (AL) amyloidosis can lead to an infiltrative cardiomyopathy with increased wall thickness (IWT) of very poor prognosis. Our primary aim was…

Subscribe to

Newsletter

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.